丹德罗比亚姆胡沙南斯茎多糖体通过调节SCFA/GLP-1轴介导的神经炎症抑制来保护阿尔茨海默病
Qiang-Ming Li1, Qiao-Qiao Zhang-Yang1, Ya-Yi Tan2
1School of Food and Biological Engineering, Anhui Province Institute of Agricultural Products Processing Technology, Hefei University of Technology, Hefei, 230009, People's Republic of China.
International journal of biological macromolecules
|March 7, 2026
概括
培养的Dendrobium huoshanense干多糖化物 (cDHPS) 在阿尔茨海默氏症 (AD) 方面显示出有前途. 它通过调节短链脂肪酸 (SCFA) 和类似葡萄糖-1 (GLP-1) 轴来改善认知和减少神经炎症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病.
- 丹朵 (Dendrobium huoshanense) 的茎是一种传统的药用食品.
- 对阿尔茨海默病治疗的天然化合物的研究至关重要.
研究的目的:
- 在Aβ1-42诱导的阿尔茨海默病小鼠模型上评估培养的D. huoshanense茎多糖体 (cDHPS) 的治疗效果.
- 阐明AD中cDHPS作用的潜在机制.
主要方法:
- 使用Aβ1-42诱导的AD小鼠模型.
- 评估了认知功能,海马神经元损伤和神经炎症标志物.
- 测量了葡萄糖类-1 (GLP-1) 和肠道短链脂肪酸 (SCFA) 的水平.
- 用GLP-1受体抗剂和SCFA枯竭来证实机制.
主要成果:
- 在AD小鼠中,cDHPS显著改善了认知功能,并减少了海马神经元损伤.
- cDHPS通过抑制NLRP3炎症酶激活,微质细胞和天体细胞激活来缓解神经炎症.
- cDHPS治疗增加了海马体,血和肠道中的GLP-1水平,同时增加了SCFA.
- 阻断GLP-1受体或耗尽SCFA降低了cDHPS的保护作用.
结论:
- cDHPS显示出对抗阿尔茨海默病的显著神经保护作用.
- 该机制涉及SCFA/GLP-1轴的调节,导致抑制的神经炎症.
- cDHPS代表了阿尔茨海默病管理的潜在治疗剂.
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K


